15963-1-AP
antibody from Proteintech Group
Targeting: PI3
cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14
Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15963-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- Elafin/Skalp antibody
- Antibody type
- Polyclonal
- Description
- Elafin/Skalp antibody (Cat. #15963-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer.
Spatiotemporal expression and regulation of peptidase inhibitor 3 and secretory leukocyte protease inhibitor at the maternal-fetal interface in pigs.
FAM3B Serves as a Biomarker for the Development and Malignancy of Oral Lichen Planus.
Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma.
Lu W, Xie B, Tan G, Dai W, Ren J, Pervaz S, Li K, Li F, Wang Y, Wang M
Frontiers in endocrinology 2023;14:1088944
Frontiers in endocrinology 2023;14:1088944
Spatiotemporal expression and regulation of peptidase inhibitor 3 and secretory leukocyte protease inhibitor at the maternal-fetal interface in pigs.
Lee S, Yoo I, Cheon Y, Ka H
Animal bioscience 2023 Jul;36(7):1034-1043
Animal bioscience 2023 Jul;36(7):1034-1043
FAM3B Serves as a Biomarker for the Development and Malignancy of Oral Lichen Planus.
Wang W, Wang M, Ahmed MMS, Zhao Y, Wu H, Musa M, Chen X
International journal of general medicine 2022;15:763-776
International journal of general medicine 2022;15:763-776
Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma.
Liu C, Zheng S, Wang S, Wang X, Feng X, Sun N, He J
Therapeutic advances in medical oncology 2021;13:17588359211006949
Therapeutic advances in medical oncology 2021;13:17588359211006949
No comments: Submit comment
No validations: Submit validation data